FDA OVERSIGHT OF CLINICAL TRIALS The US FDA and regulatory free fall

被引：0

|

作者：

Wilson, Mark

机构：

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2023年 / 380卷

关键词：

D O I：

10.1136/bmj.p85

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页数：1

相关论文

共 50 条

[41] FDA Guidances Target Cancer Clinical Trials
不详
JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (05) : 18N - 18N
[42] Eligibility criteria and clinical trials: An FDA perspective
Duggal, Mili
Sacks, Leonard
Vasisht, Kaveeta P.
CONTEMPORARY CLINICAL TRIALS, 2021, 109
[43] WOMEN IN CLINICAL-TRIALS - AN FDA PERSPECTIVE
SHERMAN, LA
TEMPLE, R
MERKATZ, RB
SCIENCE, 1995, 269 (5225) : 793 - 795
[44] FDA mandates suicide assessment in clinical trials
不详
JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2008, 46 (03) : 10 - 10
[45] FDA places clinical hold on imetelstat trials
Reactions Weekly, 2014, 1495 (1) : 2 - 2
[46] Mortality during US FDA clinical trials in patients with diabetes, hypertension, depression and schizophrenia
Khan, Arif
Mar, Kaysee Fahl
Gokul, Sagarika
Brown, Walter A.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2020, 21 (01): : 64 - 71
[47] Regulatory Silence at the FDA
Paradise, Jordan
MINNESOTA LAW REVIEW, 2018, 102 (06) : 2383 - 2412
[48] FDA regulatory reform
Beatrice, M
CURRENT OPINION IN BIOTECHNOLOGY, 1997, 8 (03) : 370 - 378
[49] Edible Cannabis Products: It Is Time for FDA Oversight
Benjamin, David M.
Fossler, Michael J.
JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (09): : 1045 - 1047
[50] Texas legitimizes path around FDA oversight
Laura DeFrancesco
Nature Biotechnology, 2012, 30 : 379 - 379

← 1 2 3 4 5 →